DGAP-News: INJEX Pharma AG / Key word(s): Contract/Regulatory Approval INJEX Pharma AG announces initial shipment of INJEX30 syringes without a needle to Canada 14.08.2012 / 17:03
---------------------------------------------------------------------
INJEX Pharma AG announces initial shipment of INJEX30 syringes without a needle to Canada Medical Marketing Canada (MMC) Inc. is the exclusive distributor in Canada for INJEX 30 and has received registration from Health Canada. INJEX Pharma AG ISIN: DE000A0STYL7 Berlin, 14 August 2012 Medical Marketing Canada (MMC) Inc. is pleased to announce it has successfully navigated the complex registration process for INJEX 30 in Canada. INJEX Pharma AG and their exclusive international partners continue to enter new countries via national registrations in numerous countries including China and India which offer significant growth opportunities for this innovative technology while delivering solutions' to help improve the quality of life. INJEX Pharma AG will deliver its initial shipment of 2500 INJEX30 System and all disposable ancillaries to 'MMC' in accordance with the contract which includes: 75% prepayment and remaining monies to be paid within several business days of shipment. 'Registration in Canada is one of the more challenging processes associated with International distribution and we are pleased our strategic partner 'MMC' met all necessary requirements. In concert with our previously announced FDA 510 K we are well positioned to execute on our sales strategy in these regions. In addition to our North American Regions we anticipate additional key registrations as we continue to execute on our vision. 'Stated Andy Roesch, CEO of INJEX Pharma AG INJEX Pharma AG markets and sells their INJEX30 System and ancillaries products worldwide. The INJEX30 technology offers needle free technology which is cost effective and painless. INJEX30 is a syringe without a needle used in multiple medical, cosmetic and anesthetic applications and may be marketed via traditional pharmaceutical and emerging life science modalities. INJEX30 targeted disease states and delivery systems include diabetes, local and dental anesthetics, allergy and fertility treatments, vaccinations, erectile dysfunction and growth hormones. INJEX Pharma AG is introducing the SHIREEN Beauty system focused on the rejuvenation of the skin. SHIREEN is being formulated to remove initial wrinkles and provide natural glow to the skin. The 'Poring method' is an innovative international cosmetic treatment for the skin. The liquid crème SHIREEN Fluid is sprayed with high pressure and within a small distance of the skin via the SHIREEN pore-jet allowing the fluid open access to pores stored in the upper layers of the skin. Contact: Andy Rösch CEO INJEX Pharma AG Buckower Damm 114 12349 Berlin Tel.: 0049-30-53096768 andy.roesch@injex.com www.injex.com Sylwin Grinman Managing Director INJEX Pharma USA 1922 NE 119 RD North Miami Beach - FL - 33181 USA Tel.: +1 786 512 196 3 sylwin@injex.com End of Corporate News
---------------------------------------------------------------------
14.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
181683 14.08.2012
---------------------------------------------------------------------
INJEX Pharma AG announces initial shipment of INJEX30 syringes without a needle to Canada Medical Marketing Canada (MMC) Inc. is the exclusive distributor in Canada for INJEX 30 and has received registration from Health Canada. INJEX Pharma AG ISIN: DE000A0STYL7 Berlin, 14 August 2012 Medical Marketing Canada (MMC) Inc. is pleased to announce it has successfully navigated the complex registration process for INJEX 30 in Canada. INJEX Pharma AG and their exclusive international partners continue to enter new countries via national registrations in numerous countries including China and India which offer significant growth opportunities for this innovative technology while delivering solutions' to help improve the quality of life. INJEX Pharma AG will deliver its initial shipment of 2500 INJEX30 System and all disposable ancillaries to 'MMC' in accordance with the contract which includes: 75% prepayment and remaining monies to be paid within several business days of shipment. 'Registration in Canada is one of the more challenging processes associated with International distribution and we are pleased our strategic partner 'MMC' met all necessary requirements. In concert with our previously announced FDA 510 K we are well positioned to execute on our sales strategy in these regions. In addition to our North American Regions we anticipate additional key registrations as we continue to execute on our vision. 'Stated Andy Roesch, CEO of INJEX Pharma AG INJEX Pharma AG markets and sells their INJEX30 System and ancillaries products worldwide. The INJEX30 technology offers needle free technology which is cost effective and painless. INJEX30 is a syringe without a needle used in multiple medical, cosmetic and anesthetic applications and may be marketed via traditional pharmaceutical and emerging life science modalities. INJEX30 targeted disease states and delivery systems include diabetes, local and dental anesthetics, allergy and fertility treatments, vaccinations, erectile dysfunction and growth hormones. INJEX Pharma AG is introducing the SHIREEN Beauty system focused on the rejuvenation of the skin. SHIREEN is being formulated to remove initial wrinkles and provide natural glow to the skin. The 'Poring method' is an innovative international cosmetic treatment for the skin. The liquid crème SHIREEN Fluid is sprayed with high pressure and within a small distance of the skin via the SHIREEN pore-jet allowing the fluid open access to pores stored in the upper layers of the skin. Contact: Andy Rösch CEO INJEX Pharma AG Buckower Damm 114 12349 Berlin Tel.: 0049-30-53096768 andy.roesch@injex.com www.injex.com Sylwin Grinman Managing Director INJEX Pharma USA 1922 NE 119 RD North Miami Beach - FL - 33181 USA Tel.: +1 786 512 196 3 sylwin@injex.com End of Corporate News
---------------------------------------------------------------------
14.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
181683 14.08.2012
